… We also used the recently developed hamster model of SARS-CoV-2 infection (29, 30)
that allowed evaluation of both prophylactic and therapeutic efficacy of IgG1 ab1, although it …

… MERS-CoV patients most likely would initiate treatment after infection, we performed a series
of therapeutic efficacy … −/− hDPP4 mice infected with 5E + 04 pfu MERS-CoV on 1 dpi: RDV …

… :02 and B*27:07 alleles were connected to COVID-19 susceptibility in 99 Italians, whereas
HLAC*01 and B*44 alleles are strongly linked to SARSCoV-2 infection in Italy. The HLA-A*11:…

… Unlike RBD-targeting neutralizing antibodies, hACE2-Fc treatment did not induce the … and
therapeutic hACE2-Fc treatments effectively protected mice from SARS-CoV-2 infection, as …

… the wild type virus. … effect in B.1.351-infected animals was confirmed with a clinical dosage
of CT-P59, suggesting that CT-P59 has therapeutic potential for COVID-19 patients infected …

… Development of effective therapy thus became an emergency. This report aims to highlight
Resveratrol as possible therapeutic candidate in SARS-CoV-2 infection. The antiviral efficacy …

… infectious diseases. Our results showed the prophylactic and therapeutic efficacy of MW05/LALA
on SARS-CoV-2 … antibody-based therapies for prophylactic and therapeutic treatment of …

… 8 hr after infection) would extend to later times post infection, we designed a therapeutic efficacy
… we varied both time of oral therapy initiation and dose level in BALB/c mice infected with …

… therapeutic efficacy of small-molecule antiviral agents for COVID-19 against these variants.
… Thus, S309 showed less therapeutic effect against infection with D614G (HP095) compared …

… COVID-19 that either show no or only limited therapeutic … demonstrate no efficacy against
SARS-CoV-2 infection. Lastly, … or insufficient data concerning their effectiveness, such as …